Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, B-Cell, Marginal Zone

Explore clinical trials studying Lymphoma, B-Cell, Marginal Zone. Study availability and eligibility vary by location and protocol.

647 public trials 86 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, B-Cell, Marginal Zone trial results

Recruiting

Epco, Zanu, Ritux for R/R FL or MZL

NCT06563596

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
Locations
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • The Ohio State University Wexner Medical Center Columbus, Ohio, United States
View Trial Details
Recruiting

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

NCT04840602

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +18 more
Locations
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • City of Hope at Irvine Lennar Irvine, California, United States
  • UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida, United States
View all 145 locations
View Trial Details
Recruiting

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

NCT07101328

Conditions
B-cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +23 more
Locations
  • City of Hope Duarte, California, United States
  • University of Colorado Denver - School of Medicine - Anschutz Medical Campus Aurora, Colorado, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Yale University School of Medicine - Yale Cancer Center New Haven, Connecticut, United States
View all 51 locations
View Trial Details
Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

NCT05006716

Conditions
B-cell Malignancy, Blood Protein Disorders, Cardiovascular Diseases, +37 more
Locations
  • University of Alabama At Birmingham Hospital Birmingham, Alabama, United States
  • Mayo Clinic Phoenix Phoenix, Arizona, United States
  • Honor Health Research Institute Scottsdale, Arizona, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
View all 115 locations
View Trial Details
Recruiting

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

NCT07225439

Conditions
B-cell Non Hodgkin Lymphoma, Chronic Disease, Chronic Lymphocytic Leukemia, +30 more
Locations
  • Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center Cleveland, Ohio, United States
  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute Cleveland, Ohio, United States
View Trial Details
Recruiting

A Study of ARC-02 in B-cell NHL

NCT07691606

Conditions
B-cell Non Hodgkin Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +21 more
Locations
  • Start Cala Los Angeles, California, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • NYU Langone New York, United States
  • Levine Cancer Institute Charlotte, North Carolina, United States
View all 29 locations
View Trial Details
Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

NCT05294731

Conditions
B-cell Malignancy, Blood Protein Disorders, Cardiovascular Diseases, +36 more
Locations
  • The First Affiliated Hospital of Bengbu Medical University Bengbu, Anhui, China
  • Anhui Provincial Hospital Hefei, Anhui, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Beijing Chao Yang Hospital,Capital Medical University Beijing, Beijing Municipality, China
View all 29 locations
View Trial Details

Related conditions